Luye Pharma’s Class 1 Innovative Antidepressant Targeting NET/DAT/GABAAR Approved for Clinical Trials in China
Shanghai, November 11, 2024 - Luye Pharma Group today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for LY03021 for the treatment of Major Depressive Disorder ...
November 11,2024
Luye Pharma Announces 2024 Half Year Results
- Strong net profit growth: 201% -
- Five new drugs approved for marketing -
Shanghai, August 28, 2024 -- Luye Pharma Group today announced its 2024 half-year results and latest developments.
During the reporting period, the total revenue was about RMB 3.07 billion, up 6% ...
August 29,2024
13
2024-08
Luye Pharma’s mRNA-based Therapeutic HPV Vaccine LY01620 Approved for Clinical Trials in China
05
2024-08
Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in China
28
2024-07
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder
23
2024-07
Luye Pharma Will Receive RMB 1.6 Billion Strategic Investment for Shenzhen Luye
04
2024-07
Luye Pharma’s Analgesic Drug Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) Approved for Marketing in China
27
2024-06
Luye Pharma’s Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI with No FDA-483 Issued
20
2024-06
Luye Pharma’s Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China
11
2024-06
Luye Pharma's Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China for Treating Schizophrenia
06
2024-06
NDA for Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch Filed in Japan for Treating Alzheimer's Dementia
29
2024-05
Boan’s Boluojia® (Denosumab) Approved for Marketing in China
